Home Blog Page 1514

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

By
Advertorial Desk
-
  • Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
  • 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
  • Complex modalities are WuXi Biologics’ core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs
  • Bispecific/multispecific antibodies are WuXi Biologics’ most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company’s revenue and delivers 120%+ YoY growth
  • Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East

SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company’s 2025 achievements and outlining its outlook.

Dr. Chen commented, “Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our ‘Follow and Win the Molecule’ strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution.”

Strong Project Funnel Achieving Record High

Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total to 945 and reinforcing its position as the partner of choice for biopharma innovators worldwide. Approximately half of the new projects originated from U.S. clients, underscoring strong client trust from the market. 

The company has excelled in three key areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities.

Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively. Together, these complex modalities now account for nearly 50% of the total pipeline, underscoring strong demand for differentiated biologics. In parallel, the company maintains a deep and diversified base of over 400 mAbs and other protein therapeutics, including multiple multi-billion-dollar franchises in late-stage development and commercial manufacturing. With strength across research, development, manufacturing, bispecific/multispecific antibodies represent WuXi Biologics’ most exciting, fastest-growing and highest‑margin modality, contributing nearly 20% of the company’s revenue and achieving YoY growth exceeding 120%.

Through its “Win-the-Molecule” strategy, WuXi Biologics has been securing a quantity of projects across different stages. In 2025, the company added 23 projects, including 6 Phase III and commercial projects. Notably, half of these projects involve complex modalities, led by bispecific/multispecific antibodies and ADCs.

Research: Accelerating Deal Momentum and Platform Inflection

Research services maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company’s CD3 platform.

The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab.

WuXi Biologics’ research services business achieved another record year in 2025, securing record-breaking upfront payments and potential milestone values exceeding USD 4 billion.

Development: Pioneering Innovative Solutions

WuXi Biologics continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing.

It launched WuXia™ TrueSite, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. The platform has achieved an average mAb titer exceeding 8.0 g/L, with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations.

The company has also expanded core technology solutions for high-dose delivery into clinical and commercial applications, including High-throughput formulation development platform WuXiHighTM, Hyaluronidase Co-Formulation platform, and large-volume devices capabilities.

Manufacturing: Advancing Growth at Speed and Scale

As the “Follow and Win the Molecule” strategy continues, the total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025. Manufacturing is positioned for accelerated growth, driven by an expanding commercial portfolio and revenue ramp per program over time.

Built on operational excellence, technology leadership and a proven quality system, WuXi Biologics completed 28 PPQs in 2025 and has 34 PPQs scheduled for 2026 based on current contracts, reflecting strong momentum in CMO services. It has achieved a 99%+ success rate on PPQ batches, ranking among the industry’s top performers. Since 2017, it has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners.

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry’s rigorous quality standards. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics passed more than 1,800 GMP quality audits led by clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients’ trust.

Global Layout: Building Strategic Hubs in the U.S., Singapore and Qatar

WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging cross‑site synergies among facilities in New Jersey and Massachusetts, the company enables the seamless transfer of materials, samples, and products across the U.S..

In Singapore, the company has commenced construction of its new modular drug product facility, while the drug substance modular facility is currently in the design phase. Meanwhile, its subsidiary WuXi XDC achieved mechanical completion of its Singapore manufacturing facility in June 2025, positioning the Singapore site as a strategic hub within the global network.

In December 2025, WuXi Biologics announced the signing of an MOU with the Qatar Free Zones Authority (QFZ). The long-term strategy is to establish the Qatar site as a strategic pillar within WuXi Biologics’ global CRDMO network, marking the company’s entry into the region while extending its global footprint and capabilities.

Global Leading Digital CRDMO: Powering World-class Speed, Quality, Operational Efficiency and Client Experience

WuXi Biologics has embedded digital innovations into every fabric of research, development, manufacturing, operations and customer engagement that truly redefined values for its partners.

The DaVinci Client Portal provides a secure, real-time interface for proposal generation, access to experimental and manufacturing data and reports, cost estimates, and shipment tracking. Lab core systems, such as BioFoundry and InSilico, accelerate discovery, development and manufacturing by enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLabTM to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.

A Leader in Industry Sustainability

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics has made significant strides in sustainability, earning widespread industry recognition. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP “A List” for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

Sustainable High Growth in 2026

In 2026, WuXi Biologics will build on strong momentum with accelerated growth driven by robust research, leading development and explosive manufacturing business. By putting clients first and leveraging its full end‑to‑end capabilities, WuXi Biologics is fast‑tracking biologics innovation for global clients and delivering meaningful benefits to patients around the world.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Business
info@wuxibiologics.com

 

US Suspends Immigrant Visa Processing for 75 Countries, Thailand, Cambodia on the List

By
Laotian Times
-
This photo is used for representational purpose only.

AFP – The United States said on 14 January it was suspending the processing of immigrant visas from 75 countries, President Donald Trump’s latest move against foreigners seeking to come to America.

The United States has long rejected visas from people who appear likely to end up needing government welfare, but the State Department said it would now use the same authority for a blanket suspension of immigrant visas based on nationality.

“The Trump administration is bringing an end to the abuse of America’s immigration system by those who would extract wealth from the American people,” State Department spokesman Tommy Pigott said.

“Immigrant visa processing from these 75 countries will be paused while the State Department reassesses immigration processing procedures to prevent the entry of foreign nationals who would take welfare and public benefits,” he said.

White House Press Secretary Karoline Leavitt posted on X that the countries affected would include Somalia, whose people Trump has attacked in heated terms after immigrants were involved in a funding scandal in Minnesota, as well as Russia and Iran.

A US official said that the other countries affected would include a number of countries with friendly relations with the United States, including Brazil, Egypt and Thailand.

Other countries to face the pause include Nigeria, Africa’s most populous country, as well as Iraq and Yemen, the official said.

The State Department did not immediately release a full list of countries.

The freeze will begin on 21 January with no set time for it to end, the US official, who was not authorized to speak to the press, said on condition of anonymity.

Trump has made no secret of his desire to reduce immigration by people who are not of European descent. He has described Somalis as “garbage” who should “go back to where they came from” and instead said he was open to Scandinavians moving to the United States.

The State Department said Monday that it has revoked more than 100,000 visas since Trump’s return, a one-year record.

The Department of Homeland Security last month said that the Trump administration has deported more than 605,000 people, and that 2.5 million others left on their own.

The latest move does not affect tourist, business or other visas, including for soccer fans seeking to visit for this year’s World Cup, although the Trump administration has vowed to vet all applicants’ social media histories.

© Agence France-Presse

Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus

By
Advertorial Desk
-

– UCSD’s Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses ‘Xafty’ as “The weapon to end the virus war.” 
– Announces “One Drug, Two Tracks” strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. 
– Dr. Davey Smith: “With this multi-virus treatment, 2026 may mark the inaugural year of modern treatments that can treat multiple viruses with one drug, perhaps even viruses that haven’t hit us yet.”

SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — Hyundai Bioscience (KOSDAQ: 048410) today announced a groundbreaking roadmap to combat global viral epidemics, officially declaring its entry into Phase 2 clinical trials in the United States.

Presenting at the Biotech Showcase 2026, the company unveiled its pre-emptive therapeutic strategy using Xafty™, a broad-spectrum antiviral drug. The presentation highlighted a bold transition: “Preparation in Vietnam is complete. Now, it is America.”

– Dr. Davey Smith: “The Broad-Spectrum Weapon We Have Been Waiting For.”

The core of the announcement centered on the clinical strategy designed in collaboration with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD).

Dr. Smith, a world-renowned expert who previously led the U.S. government’s ACTIV-2 COVID-19 trials, diagnosed the current U.S. healthcare crisis as a “tripledemic” of Influenza, RSV, and COVID-19 variants, for which there is no unified countermeasure.

In a statement regarding the new clinical design, Dr. Smith emphasized, “We now have a promising weapon to fight multiple viruses at the same time. Xafty’s ‘Basket Trial’ design is the only efficient way to solve this multi-viral crisis.” He further urged, “There is no time to lose. We must proceed with the trials necessary with maximum speed to deliver this solution to patients who are currently defenseless.”

– “One Drug, Two Tracks”: A Universal Solution

Hyundai Bioscience presented its unique “One Drug, Two Tracks” global strategy. The company is using the same drug (Xafty) to target:

* Dengue Fever in Vietnam (Track 1)

* Upper-Respiratory Infection Viruses in the US (Track 2)

This approach validates the drug’s breadth and potency, demonstrating its potential to treat both mosquito-borne and respiratory viral infections. This mechanism is analogous to modern antibiotics that can treat multiple bacterial types with a single drug.

Mr. Jason Kim, CEO of Hyundai Bioscience USA, stated, “At the showcase, we confirmed that our strategy, designed with Dr. Smith, perfectly aligns with the unmet needs of the U.S. medical field. Our preparation is complete. We are ready to submit our IND application to the FDA immediately.”

– Vision: “2026, The Inaugural Year of a Virus-Free Era”

The announcement concluded with a historic vision for global public health, articulated by Dr. Smith. “For too long, we have been chasing after variants,” Dr. Smith noted. “But with this pre-emptive, broad-spectrum approach, we are finally getting ahead of the curve. I am confident that this trial will be a turning point for modern antivirals that can tackle multiple viruses with one drug.”

About Hyundai Bioscience:

Hyundai Bioscience is a biotechnology company focused on developing novel drug delivery systems (DDS) to repurpose existing drugs for new therapeutic applications. The company is a member of the US Medical CBRN Defense Consortium (MCDC). Its lead candidate, Xafty (CP-COV03), is an oral antiviral drug based on niclosamide, modified for enhanced bioavailability.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update these statements except as required by law.

Media Contact:
Jason Kim
gbd@hyundaibio.com
(562)964-3910

“Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show” Proudly Supported by Manulife

By
Advertorial Desk
-

HONG KONG and MACAU, Jan. 15, 2026 /PRNewswire/ — Manulife Hong Kong and Macau (“Manulife”) is proud to support “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show,” underscoring its commitment to mental well-being as an essential pillar of holistic health and spreading joy across the community by bringing people together through laughter and shared experiences. The occasion is especially meaningful as Manulife celebrates 30 years of serving the Macau community with trusted financial solutions and guidance, alongside its ongoing dedication to promoting emotional wellness.

Manulife Hong Kong and Macau is proud to support "Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show"
Manulife Hong Kong and Macau is proud to support “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show”

The show offers a fresh entertainment experience featuring international film star and stand-up comedy icon Jimmy O. Yang. Audiences can look forward to a vibrant mix of stand-up comedy, live performances, and guest engagement, complemented by special guest appearances from Jackson Wang, Tyson Yoshi and Wan Kwong — each bringing their own flair to create a festive and unforgettable event.

Event Details:
Dates & Times: February 21, 2026 (Saturday) at 8:00 PM and February 22, 2026 (Sunday) at 6:00 PM
Venue: Galaxy Arena
Ticket Prices: HKD/MOP 880 / 780 / 680 / 480 / 380
Language: Primarily in English, with occasional Cantonese and Mandarin

“As we celebrate 30 years in Macau, we are excited to support an event that fosters emotional connection and brings people together,” said Celia Ling, Chief Marketing Officer of Manulife Hong Kong and Macau. “We believe true well-being goes beyond financial security – it encompasses physical wellness and mental health. By supporting this event, we hope to create meaningful experiences for customers and inspire families to embrace a holistic approach to living well.”

Manulife continues to empower people to make decisions easier and lives better, helping communities thrive through innovative solutions and strong partnerships. This commitment to the community is reflected by our enduring presence in Macau, soon to be symbolized by the renaming of our Macau office building to Manulife Plaza. 

For more information about “Galaxy Macau Presents: The Jimmy O. Yang Chinese New Year Show”, please visit https://www.manulife.com.mo/en/individual/promotions/jimmy-o-yang-show.html.

About Manulife Hong Kong and Macau

Manulife Hong Kong has been a trusted name for more than 125 years, while we have served the Macau market for nearly three decades. Since our operations began in Asia in 1897, we have grown into one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.

Manulife Hong Kong and Macau, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.

About Manulife

Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong.

Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.

YTL Cement’s CDL Academy and Universiti Teknologi Malaysia Sign MoU to Advance Talent Development and Research Innovation in Sustainable Construction

By
Advertorial Desk
-

PETALING JAYA, MALAYSIA – Media OutReach Newswire – 15 January 2026 – CDL Academy Sdn. Bhd. (CDL Academy), the learning and development arm of YTL Cement Group, and Universiti Teknologi Malaysia (UTM) have signed a Memorandum of Understanding (MoU) on 9 January 2026 to strengthen collaboration in talent development, applied learning, and sustainable construction practices for Malaysia’s engineering sector.

(from left to right): Datuk Aziyah Mohamed, Co-chairman of CDL Academy Sdn. Bhd., Dato’ Sr. Mohd Zaid Zakaria, Chairman of CDL Academy Sdn. Bhd., Prof. Dr. Mohd Shafry Bin Mohd Rahim, Vice-Chancellor of Universiti Teknologi Malaysia, and Associate Professor Ir. Dr. Noor Nabilah Sarbini, Director, Forensic Engineering Centre of Universiti Teknologi Malaysia during the Memorandum of Understanding signing ceremony between CDL Academy Sdn. Bhd. and Universiti Teknologi Malaysia.
(from left to right): Datuk Aziyah Mohamed, Co-chairman of CDL Academy Sdn. Bhd., Dato’ Sr. Mohd Zaid Zakaria, Chairman of CDL Academy Sdn. Bhd., Prof. Dr. Mohd Shafry Bin Mohd Rahim, Vice-Chancellor of Universiti Teknologi Malaysia, and Associate Professor Ir. Dr. Noor Nabilah Sarbini, Director, Forensic Engineering Centre of Universiti Teknologi Malaysia during the Memorandum of Understanding signing ceremony between CDL Academy Sdn. Bhd. and Universiti Teknologi Malaysia.

The MoU was signed by UTM Vice Chancellor Prof. Dr. Mohd Shafry Mohd Rahim and CDL Academy Chairman Dato’ Sr. Mohd Zaid Zakaria. It formalises the ongoing partnership between the two organisations and aims to provide students with industry exposure and practical experience, preparing them for careers in the construction sector.

Under the agreement, UTM and CDL Academy will pursue initiatives including professional training programmes, student internships, academic exchanges, workshops, seminars, and innovation projects in green building materials, advanced construction technologies, and cost management solutions.

Universiti Teknologi Malaysia (UTM) is Malaysia’s premier university for engineering, science, and technology, committed to building partnerships that enrich research output and provide students with real-world learning opportunities. The collaboration with CDL Academy exemplifies UTM’s efforts to equip graduates with the skills and experience needed to contribute effectively to the nation’s development.

Since its inception in 2019, CDL Academy has delivered over 100 seminars and learning engagements, benefiting more than 10,000 participants across the construction and engineering ecosystem. The collaboration with UTM expands these efforts, supporting the development of industry-ready graduates and addressing emerging needs in sustainable construction and advanced building technologies.

The MoU will be in effect for three years, with opportunities for renewal. Coordinators from both parties will oversee programme development to ensure measurable outcomes for students, researchers, and the construction industry.
Hashtag: #YTLCement, #CDLAcademy, #UTM, #ESG, #Sustainability, #Construction, #SustainableConstruction


The issuer is solely responsible for the content of this announcement.

CDL Academy Sdn Bhd

CDL Academy Sdn. Bhd. is the professional learning and development platform of the YTL Cement Group, established to support training and talent development within the construction industry. CDL Academy focuses on developing well-trained, industry-ready professionals through structured training and practical knowledge-sharing.

Beyond technical disciplines, CDL Academy serves as a hub for knowledge exchange, innovation and collaboration. It brings together practitioners, academics and universities, as well as industry leaders, industry associations and governing bodies through training programmes, seminars, workshops and strategic partnerships.

Through its commitment to quality education and best-practice sharing, CDL Academy aims to contribute to strengthening industry talent pipelines, supporting university–industry collaboration, and supporting the long-term advancement and sustainability of the construction ecosystem.

Universiti Teknologi Malaysia (UTM)

Universiti Teknologi Malaysia (UTM) is a premier public research university in Malaysia, specialising in engineering, science and technology. Located in Johor Bahru and with a campus in Kuala Lumpur, UTM is committed to producing globally competitive graduates and advancing cutting-edge research that addresses national and global challenges.

BTS Kicks Off a ‘New Era’ in South Korea with World Tour – Agoda Reports 8x Increase in Searches to Goyang

By
Advertorial Desk
-

SINGAPORE, Jan. 15, 2026 /PRNewswire/ — Digital travel platform Agoda has witnessed a rise in travel interest to South Korea’s Goyang and Busan as well as other key tour cities following the announcement of BTS’s world tour dates earlier this week. This marks the group’s first tour after a four-year hiatus, and fans are ready to “spring day” into action to catch their favorite group live. Following the announcement of their tour dates on Tuesday, Agoda observed a nearly 8x increase in accommodation searches to Goyang, where BTS’s tour will kick off on April 9 and continue on April 11-12, compared to the week before. Busan has also seen a 47% rise in searches, as fans prepare to “run” to these iconic concert destinations.

The announcement has ignited a wave of excitement among BTS fans across Asia, with the highest travel interest to South Korean tour destinations coming from Japan, Taiwan, the Philippines, Hong Kong, and China. Notably, searches to Busan and Goyang from the Philippines increased by over 7x, while Hong Kong saw a 145% rise, with fans eager to catch BTS before their scheduled March 2027 concert dates in Manila and Hong Kong. Meanwhile, searches from China have more than doubled, with fans “burning up” to experience BTS live, given the absence of a planned stop in their market.

Beyond South Korea’s Goyang and Busan, other Asian cities are also experiencing a “mic drop” in search activity. Kaohsiung has seen a 2x increase in searches, and Tokyo has experienced an 18% rise in searches following this week’s announcement of BTS tour dates, indicating that fans are willing to travel far and wide to be part of the BTS Army.

Matteo Frigerio, Chief Marketing Officer at Agoda shared, “BTS fans are truly ‘dynamite’ in their enthusiasm, and Agoda is thrilled to help them experience the ‘euphoria’ of catching the K-pop group live at these exciting tour destinations. With Agoda, fans can easily plan their trips and ensure they don’t miss a beat of the BTS magic, all while enjoying great deals on accommodations and flights.”

As fans prepare to “go go” on their BTS journey, Agoda offers over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all of which can be combined in the same booking. For the best deals, fans are encouraged to check out Agoda’s mobile app or visit Agoda.com.

WeLab completes US$220 million Series D strategic financing, marking the largest digital banking capital raise in Asia in 2025

By
Advertorial Desk
-

HONG KONG, Jan. 15, 2026 /PRNewswire/ — WeLab, a leading pan-Asian fintech platform, announced the successful closing of its Series D strategic financing, securing US$220 million in funding. This marks the largest digital banking capital raise in Asia for 2025 and the largest funding round since WeLab’s inception, demonstrating strong investor confidence in WeLab’s vision and scalable growth trajectory.

The financing round, comprising both debt and equity, secured investment from a diverse array of new investors, alongside strong support from existing investors and strategic capital partners, including Prudential Hong Kong Ltd, Fubon Bank (Hong Kong), Hong Kong Investment Corporation (HKIC) (announced earlier in April 2025), TOM Group (follow-on investment), Allianz X (follow-on investment), and HSBC.

The investment will fuel WeLab’s expansion in Southeast Asia, while deepening its leadership in Hong Kong through a richer, more diversified product ecosystem and accelerated customer acquisition. It will also power the creation of innovative business lines leveraging advanced technologies, drive continuous product and platform enhancements, and support strategic M&A opportunities. These initiatives reinforce WeLab’s ambition to establish Asia’s leading regional digital bank, reimagining the future of financial services.

This raise will also support the initiatives towards WeLab’s recently announced AI vision and its AI-first strategic partnership with Google, aimed at reimagining digital banking innovation across Asia. The investment will drive the development of advanced AI agents, hyper-personalization capabilities, and modernized marketing approaches, delivering more engaging customer experiences and efficient business outcomes.

Building on WeLab’s market leadership in Hong Kong, where WeLab Bank is the largest digital bank by revenue and recognized as one of the World’s Top 20 Digital Banks by Euromoney, WeLab Bank has earned multiple industry accolades throughout 2025, including “Best Digital Bank for Consumers – Hong Kong” by the Euromoney Awards for Excellence 2025 and “Best Digital Bank – Hong Kong” and “Best Bank for Financial Inclusion – Hong Kong” by the FinanceAsia Awards 2025. AI delivery will be a key driver of scale, product breadth, and ongoing innovation. By integrating cutting-edge AI solutions, WeLab is poised to set new standards for digital banking, both in Hong Kong, Indonesia’s Bank Saqu and throughout the region.

Simon Loong, Founder and Group CEO of WeLab, said, “With operations across three markets and two digital banks in Hong Kong and Indonesia, WeLab has built both scale and depth of operational experience. This foundation, proven by our rapid customer growth and market leadership, gives us the strength to capture new opportunities, accelerate expansion, and innovate at pace. In today’s dynamic landscape, we stand at the best time, with the best scale, to lead the next chapter of digital banking in Asia.”

About WeLab

WeLab, a leading pan-Asian fintech platform, operates two digital banks as well as multiple online financial services with leading positions in Hong Kong, Mainland China, and Indonesia, with over 70 million individual users and over 700 enterprise customers. WeLab uses game-changing technology to help customers access credit, save money, and enjoy their financial journey.

Powered by proprietary risk management technology, patented privacy computing techniques, and advanced AI capabilities, WeLab offers mobile-based consumer financing solutions and digital banking services to retail individuals and technology solutions to enterprise customers.

WeLab operates in three markets under several key brands, including WeLend, and WeLab Bank in Hong Kong, various business lines in Mainland China, and Bank Saqu in Indonesia.

WeLab is backed by the most renowned investors including Allianz X, China Construction Bank International, International Finance Corporation, Malaysian sovereign wealth fund Khazanah Nasional Berhad, TOM Group, and Sequoia Capital.

To learn more, please visit: www.welab.co, or follow WeLab on LinkedIn and Facebook.

Media enquiry: 
WeLab Group Communications Team
Email:  pr@welab.co

International Healthcare Week Returns to Thailand in 2026 with Expanded Industry Reach

By
Advertorial Desk
-

BANGKOK, Jan. 15, 2026 /PRNewswire/ — International Healthcare Week is set to return to Thailand (8-10 July 2026, Queen Sirikit National Convention Center, Bangkok), bringing together the region’s most influential health and wellness stakeholders. Organised by Informa Markets, this flagship event will co-locate three major exhibitions: CPHI South East Asia, WHX Bangkok (formerly Medlab Asia and Asia Health), and Medtec Southeast Asia. These events will unite cutting-edge pharmaceutical, medical device, medical laboratory and design and manufacturers of medical devices under one roof, attracting an expected 26,000+ visitors.

Demonstrating Informa’s strong commitment to expanding and deepening industry networks, International Healthcare Week 2026 will feature over 1,000 leading local, regional and international exhibitors. This expansion underscores the event’s vital role as a strategic platform to advance the health and wellness industry throughout Southeast Asia.

By uniting pharmaceutical, medical device, medical laboratory, and medical technology manufacturing, International Healthcare Week 2026 plays a critical role in accelerating regional healthcare integration and improving health outcomes for diverse communities. The event supports Southeast Asia’s healthcare priorities, promoting sustainable development and advanced medical technologies that benefit the entire region.

The events’ collaborative approach empowers stakeholders to share knowledge, build partnerships, and create scalable solutions tailored to the unique challenges faced by Southeast Asia countries. This cultivates a robust healthcare ecosystem that enhances access, quality, and affordability of care.

WHX Bangkok, CPHI South East Asia, and Medtec Southeast Asia come together during International Healthcare Week in Bangkok, creating a comprehensive platform that unites healthcare innovation, pharmaceutical advancements, and medical technology solutions under one roof.
WHX Bangkok, CPHI South East Asia, and Medtec Southeast Asia come together during International Healthcare Week in Bangkok, creating a comprehensive platform that unites healthcare innovation, pharmaceutical advancements, and medical technology solutions under one roof.

International Healthcare Week 2026 promises to be an unparalleled convergence of industry expertise and business opportunities, strengthening Southeast Asia’s collective capacity in health innovation and delivering lasting impact across the region.

“Thailand is at the heart of Southeast Asia’s rapidly growing healthcare market, making it the perfect location to showcase our biosensor technology. WHX Bangkok offered an excellent opportunity to connect with prospective buyers and strengthen relationships with existing partners. This platform aligned seamlessly with our goals of expanding our presence in Asia, reaffirming our leadership in the diagnostic market, and driving sustainable growth in the region.” Haeun Jung, Global Marketing Manager, i-SENS, Korea

“Participating in CPHI South East Asia has been an incredible experience for us! This event serves as a dynamic platform to connect with our valued customers, explore emerging market trends, and gain valuable industry insights. Our goal in being part of CPHI South East Asia is to strengthen our presence in the region, build meaningful relationships with customers, and proudly showcase our innovative drug delivery systems, active material science solutions, and services that advance patient care and improve treatment outcomes.” Anand Hiremath, Vice President, Aptar Pharma, India.

With the theme “Local & Regional to Global Networking,” the event aims to empower companies to scale their businesses from local markets to the wider global stage.

With a focus on addressing the needs of around 700 million Southeast Asia citizens, the event fosters innovation, delivers cutting-edge healthcare solutions, and encourages knowledge transfer and cross-border collaboration among industry leaders, policymakers, and investors.

Thailand – Southeast Asia’s Hub for Healthcare Innovation

Thailand’s robust infrastructure, supportive regulatory environment, and flourishing innovation ecosystem make it an ideal gateway for Southeast Asia-wide healthcare development. Positioned as a major regional hub, International Healthcare Week 2026 reinforces Thailand’s growing role as a centre for healthcare, medical technology, and pharmaceutical development. This premier event offers unparalleled opportunities for forging new partnerships, attracting investments, and driving market expansion throughout the health ecosystem in ASEAN and beyond.

Be Part of International Healthcare Week 2026

The event offers unmatched opportunities to build meaningful partnerships and contribute to shaping the future of healthcare in Southeast Asia and extend global impact. Don’t miss the chance to advance your career and position yourself at the forefront of healthcare evolution.

For more information and registration details, please visit https://inthealthcareweek.com/

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

For Media enquiries, please contact:

Gautam Jatwani
Senior Marketing Manager
Informa Markets
Gautam.jatwani@informa.com 

1...1,5131,5141,515...6,701Page 1,514 of 6,701